Last reviewed · How we verify
combination of irinotecan and cisplatin
combination of irinotecan and cisplatin is a Topoisomerase inhibitor and platinum-based chemotherapy Small molecule drug developed by Japan Clinical Oncology Group. It is currently in Phase 3 development for Metastatic colorectal cancer, Non-small cell lung cancer.
Irinotecan inhibits topoisomerase I, while cisplatin induces DNA crosslinks, both mechanisms leading to cell death in rapidly dividing cancer cells.
Irinotecan inhibits topoisomerase I, while cisplatin induces DNA crosslinks, both mechanisms leading to cell death in rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Non-small cell lung cancer.
At a glance
| Generic name | combination of irinotecan and cisplatin |
|---|---|
| Sponsor | Japan Clinical Oncology Group |
| Drug class | Topoisomerase inhibitor and platinum-based chemotherapy |
| Target | Topoisomerase I and DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Irinotecan works by inhibiting topoisomerase I, an enzyme involved in DNA replication, causing DNA damage and triggering cell death. Cisplatin, on the other hand, forms DNA crosslinks, which also lead to cell death. Both mechanisms are particularly effective against rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Diarrhea
- Anemia
- Thrombocytopenia
Key clinical trials
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (PHASE1)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction (PHASE2)
- A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (PHASE2)
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery (PHASE3)
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- combination of irinotecan and cisplatin CI brief — competitive landscape report
- combination of irinotecan and cisplatin updates RSS · CI watch RSS
- Japan Clinical Oncology Group portfolio CI
Frequently asked questions about combination of irinotecan and cisplatin
What is combination of irinotecan and cisplatin?
How does combination of irinotecan and cisplatin work?
What is combination of irinotecan and cisplatin used for?
Who makes combination of irinotecan and cisplatin?
What drug class is combination of irinotecan and cisplatin in?
What development phase is combination of irinotecan and cisplatin in?
What are the side effects of combination of irinotecan and cisplatin?
What does combination of irinotecan and cisplatin target?
Related
- Drug class: All Topoisomerase inhibitor and platinum-based chemotherapy drugs
- Target: All drugs targeting Topoisomerase I and DNA
- Manufacturer: Japan Clinical Oncology Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Non-small cell lung cancer
- Compare: combination of irinotecan and cisplatin vs similar drugs
- Pricing: combination of irinotecan and cisplatin cost, discount & access